BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

NCT04777708 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Withdrawn by sponsor

Conditions

Advanced Hepatocellular Carcinoma
BCLC Stage B Hepatocellular Carcinoma
BCLC Stage C Hepatocellular Carcinoma
Refractory Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Nanoplexed Poly I:C BO-112
BIOLOGICAL: Pembrolizumab

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]